Poxel Announces its Participation at Investor Conferences in October 2021

POXEL SA (Euronext POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its participation at upcoming investor conferences in October 2021.